Neoplasms, Hormone-Dependent
"Neoplasms, Hormone-Dependent" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
| Descriptor ID |
D009376
|
| MeSH Number(s) |
C04.626
|
| Concept/Terms |
Neoplasms, Hormone-Dependent- Neoplasms, Hormone-Dependent
- Neoplasms, Hormone Dependent
- Hormone-Dependent Neoplasms
- Hormone Dependent Neoplasms
- Hormone-Dependent Neoplasm
- Neoplasm, Hormone-Dependent
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Hormone-Dependent".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Hormone-Dependent".
This graph shows the total number of publications written about "Neoplasms, Hormone-Dependent" by people in this website by year, and whether "Neoplasms, Hormone-Dependent" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms, Hormone-Dependent" by people in Profiles.
-
Yu EY, Getzenberg RH, Coss CC, Gittelman MM, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Hancock ML, Smith J, Dalton JT, Steiner MS. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):334-41.
-
Wills MK, Jones N. Teaching an old dogma new tricks: twenty years of Shc adaptor signalling. Biochem J. 2012 Oct 01; 447(1):1-16.
-
Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL, Neugut AI, Santella RM. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009 Jun; 2(6):598-604.
-
Sinha R, Pinto JT, Facompre N, Kilheffer J, Baatz JE, El-Bayoumy K. Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. Nutr Cancer. 2008; 60(2):267-75.
-
Hrushesky WJ, Retsky M, Baum M, Demicheli R. Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007 Jul 04; 99(13):1053; author reply 1053-4.
-
Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer. 2005 12; 12(4):721-47.
-
Macpherson GR, Singh AS, Bennett CL, Venzon DJ, Liewehr DJ, Franks ME, Dahut WL, Kantoff PW, Price DK, Figg WD. Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biol Ther. 2004 Dec; 3(12):1298-303.
-
Creasman WT. Estrogen and cancer. Gynecol Oncol. 2002 Jul; 86(1):1-9.
-
Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev. 2000; (2):CD001526.
-
Orr RK, Col NF, Kuntz KM. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. Surgery. 1999 Sep; 126(3):568-76.